Abstract
There has been an increasing interest in compounds that modulate potassium ion channels (K+-channels) since they can be developed as important therapeutic agents against ischemic heart diseases. Of the diverse family of K+- channels, the voltage-gated potassium channel Kv1.3 constitutes an attractive target for the selective suppression of effector memory T cells in autoimmune diseases. For the development of antiarrythmic drugs, the blockade of the rapidly activating delayed rectifier (IKr) and slowly activating delayed rectifier (IKs) potassium currents has been specifically studied. Since the discovery of IKs-channel, its blockers have been particularly more studied. In this communication, we present QSAR studies on a few series of Kv1.3-channel blockers and a series of IKs-channel blockers in order to provide some guidelines to the drug development.
Keywords: Quantitative structure-activity relationship study, potassium channel blockers, Kv1.3-channel blockers, IKschannel blockers, khellinone analogs, chromanols
Medicinal Chemistry
Title: A Quantitative Structure-Activity Relationship Study on Some Series of Potassium Channel Blockers
Volume: 5 Issue: 1
Author(s): V. S.A. Kumar Satuluri, Jyostna Seelam and S. P. Gupta
Affiliation:
Keywords: Quantitative structure-activity relationship study, potassium channel blockers, Kv1.3-channel blockers, IKschannel blockers, khellinone analogs, chromanols
Abstract: There has been an increasing interest in compounds that modulate potassium ion channels (K+-channels) since they can be developed as important therapeutic agents against ischemic heart diseases. Of the diverse family of K+- channels, the voltage-gated potassium channel Kv1.3 constitutes an attractive target for the selective suppression of effector memory T cells in autoimmune diseases. For the development of antiarrythmic drugs, the blockade of the rapidly activating delayed rectifier (IKr) and slowly activating delayed rectifier (IKs) potassium currents has been specifically studied. Since the discovery of IKs-channel, its blockers have been particularly more studied. In this communication, we present QSAR studies on a few series of Kv1.3-channel blockers and a series of IKs-channel blockers in order to provide some guidelines to the drug development.
Export Options
About this article
Cite this article as:
Kumar Satuluri S.A. V., Seelam Jyostna and Gupta P. S., A Quantitative Structure-Activity Relationship Study on Some Series of Potassium Channel Blockers, Medicinal Chemistry 2009; 5 (1) . https://dx.doi.org/10.2174/157340609787049244
DOI https://dx.doi.org/10.2174/157340609787049244 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Antithrombotic Therapy After TAVR
Current Vascular Pharmacology Conjugation of Resveratrol with RGD and KGD Derivatives
Protein & Peptide Letters Predictors of Ominous Outcome in Infants who Undergo Cardiac Surgery and Cardiopulmonary By-Pass: S100B Protein
CNS & Neurological Disorders - Drug Targets Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Synthesis and Biological Evaluation of N-(Alkyl)-2-Thiophen-2-Ylacetamides Series As A New Class of Antitubercular Agents
Letters in Drug Design & Discovery Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Subject Index to Volume 1
Current Vascular Pharmacology Hypertension in Older Patients
Current Hypertension Reviews Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nutritional Antioxidants and Their Applications in Cardiometabolic Diseases
Infectious Disorders - Drug Targets Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Atherogenesis in White Coat Hypertension
Current Hypertension Reviews Reproductive Effects of Low-to-Moderate Medical Radiation Exposure
Current Medicinal Chemistry Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design